Trump and AstraZeneca Forge Drug Pricing Agreement to Lower Medicaid Costs

President Donald Trump announced a deal with AstraZeneca to provide discounted medications for Medicaid, aiming to reduce U.S. prescription drug costs amid ongoing pharmaceutical industry reforms.

On Friday, President Donald Trump revealed a pricing agreement with AstraZeneca to lower Medicaid costs by offering some medications at a discount in exchange for tariff relief.
This agreement follows a similar pact reached last week with Pfizer, reinforcing the White Houses strategy to negotiate better deals with the pharmaceutical industry for U.S. consumers.
The deal with AstraZeneca is part of a broader initiative by the Trump administration to tackle high prescription drug prices, which have become a significant concern for American healthcare.

Por Qué Es Relevante

This agreement highlights the Trump administrations efforts to combat rising prescription drug prices in the United States, potentially impacting millions of Medicaid recipients and shaping future negotiations within the pharmaceutical industry.